SPECIFIC AIMS
Ovarian cancer is the most lethal gynecological disease. 70-80% of ovarian cancer patients are diagnosed at
stage III or IV when peritoneal metastasis has already occurred. The unique metastasis pattern in ovarian cancer
involves the detachment of tumor cells, diffusion through the intraperitoneal space and attachment to the
mesothelial layer lining the omentum and abdominal organs. Both increased collagen deposition and
extracellular matrix (ECM) stiffening (due to altered collagen architecture) by stromal cells can create a pro-
metastatic environment. Paracrine action of tumor growth-inducing molecules like polyamines can also promote
metastasis. Identifying mechanisms that underlie collagen deposition and polyamine synthesis will allow better
understanding of metastasis and thus further development of therapeutic interventions.
One putative candidate for regulating metastasis is the fibrillar collagen-binding receptor tyrosine kinase
Discoidin Domain Receptor-2 (DDR2). DDR2 expression is increased in the stroma of high grade serous ovarian
cancer (HGSOC) patients and this increase is, alone, associated with shorter survival and worse response to
therapy. We found that there were fewer intraperitoneal tumors when DDR2-expressing tumor cells were injected
into the peritoneal cavity of syngeneic Ddr2-/- mice vs WT mice. To understand molecular reasons for this
difference I performed targeted mRNA sequencing of tumors from Ddr2 WT and Ddr2-/- mice and found that
expression of Arginase-1 was highly down-regulated in tumors from Ddr2-/- mice. Moreover, I found that shRNA
depletion of DDR2 in WT ovarian omental cancer-associated fibroblasts also significantly decreased Arginase-
1 expression and activity. A major metabolic function of Arginase-I in cells is to promote arginine degradation
into ornithine, which is a source of proline for collagen synthesis and polyamines that can impact cellular
proliferation.
Based upon these, and other, compelling preliminary data I propose to test the hypothesis: DDR2-regulated
Arginase-1 expression in ovarian cancer omental CAFs promotes metastasis by impacting collagen production
and ECM organization as well as polyamine synthesis. I will test this hypothesis by pursuing two specific aims:
Aim 1: Determine the role of intracellular Arginase-1 in omental cancer-associated fibroblasts on collagen
synthesis and architecture. Aim 2: Determine the role of intracellular Arginase-1 on polyamine-mediated tumor
cell metastasis. These studies will uncover novel mechanisms by which DDR2 regulates arginase-1 in omental
CAFs and how arginase-1 promotes metastasis through increased collagen deposition and polyamine synthesis.
As DDR2 has been implicated in lung, pancreatic, and breast cancer, my findings may have broad implications
in other cancers. This project will encourage my scientific growth as a physician scientist-in-training.
Public Health Relevance Statement
PUBLIC NARRATIVE
Ovarian cancer has a unique metastatic pattern and stromal cells including cancer-associated fibroblasts (CAFs)
play a key role in the metastatic process. I aim to study the role of omental CAF Discoidin domain receptor 2
(DDR2) in cancer cell metastasis, especially through its regulation of arginase-1. This study will uncover novel
mechanisms by which omental CAF DDR2 and arginase alter collagen remodeling and polyamine biosynthesis,
and may support development of novel therapies for ovarian cancer patients in the future.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AbdomenAnabolismArchitectureArginineBiological AssayCancer PatientCell ProliferationCellsChemoresistanceCollagenDataDepositionDevelopmentDiffusionEnvironmentEnzymesExtracellular MatrixFemale Genital DiseasesFibrillar CollagenFibroblastsFutureGreater sac of peritoneumGrowthHumanIn VitroKnock-outMalignant Breast NeoplasmMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of ovaryMalignant neoplasm of pancreasManuscriptsMass Spectrum AnalysisMediatingMesenchymalMesothelial CellMesotheliumMetabolicMolecularMusNeoplasm MetastasisOmentumOrganOrnithineOrnithine DecarboxylaseOvarianPatternPeritonealPhysiciansPlayPolyaminesProductionProlineReceptor Protein-Tyrosine KinasesRegulationRoleScientistSerousSourceStage at DiagnosisStromal CellsStromal NeoplasmTestingTherapeutic InterventionTrainingTumor BurdenTumor Cell Invasionarginasecancer celldiscoidin domain receptor 2in vivointraperitonealmRNA sequencingmetastatic processmouse modelneoplastic cellnovelnovel therapeuticsovarian neoplasmoverexpressionparacrinereceptor bindingresponsesmall hairpin RNAtherapeutic developmenttreatment responsetumortumor growthtumor microenvironment
No Sub Projects information available for 5F30CA278318-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30CA278318-02
Patents
No Patents information available for 5F30CA278318-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30CA278318-02
Clinical Studies
No Clinical Studies information available for 5F30CA278318-02
News and More
Related News Releases
No news release information available for 5F30CA278318-02
History
No Historical information available for 5F30CA278318-02
Similar Projects
No Similar Projects information available for 5F30CA278318-02